» Articles » PMID: 37414740

Cancer Incidence and Type of Treatment Hospital Among Children, Adolescents, and Young Adults in Japan, 2016-2018

Overview
Journal Cancer Sci
Specialty Oncology
Date 2023 Jul 6
PMID 37414740
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer in children, adolescents, and young adults (AYAs) although rare, is the leading disease-specific cause of death in Japan. This study aims to investigate cancer incidence and type of treatment hospital among children and AYAs in Japan. Cancer incidence data (2016-2018) for those aged 0-39 years were obtained from the Japanese population-based National Cancer Registry. Cancer types were classified according to the 2017 update of the International Classification of Childhood Cancer (Third Edition), and AYA Site Recode 2020 Revision. Cases were also categorized into three groups: those treated at core hospitals for pediatric cancer treatment (pediatric cancer hospitals [PCHs]), those treated at designated cancer care hospitals, and those treated at nondesignated hospitals. The age-standardized incidence rate was 166.6 (per million-person years) for children (age 0-14 years) and 579.0 for AYAs (age 15-39 years) (including all cancers and benign or uncertain-behavior central nervous system [CNS] tumors). The type of cancer varied with age: hematological malignancies, blastomas, and CNS tumors were common in children under 10 years, malignant bone tumors and soft tissue sarcomas were relatively common in teenagers, and in young adults over 20 years, carcinomas in thyroid, testis, gastrointestinal, female cervix, and breast were common. The proportion of cases treated at PCHs ranged from 20% to 30% for children, 10% or less for AYAs, and differed according to age group and cancer type. Based on this information, the optimal system of cancer care should be discussed.

Citing Articles

Comparison of lifetime attributable risk of post-irradiation secondary cancer of boron neutron capture therapy, proton beam therapy, and X-ray therapy for pediatric and adolescent and young adult patients.

Suzuki S, Shiba S, Tanaka H, Yamanaka M, Matsumoto K, Tokuuye K Clin Transl Radiat Oncol. 2025; 51:100921.

PMID: 39898334 PMC: 11786841. DOI: 10.1016/j.ctro.2025.100921.


Epidemiology and clinical features of childhood malignant solid tumors in a single center in southwest China over 24 years.

Li T, Kong X, He D BMC Pediatr. 2025; 25(1):12.

PMID: 39773427 PMC: 11706053. DOI: 10.1186/s12887-024-05360-3.


Population Pharmacokinetics of Tamibarotene in Pediatric and Young Adult Patients with Recurrent or Refractory Solid Tumors.

Azechi T, Fukaya Y, Nitani C, Hara J, Kawamoto H, Taguchi T Curr Oncol. 2024; 31(11):7155-7164.

PMID: 39590158 PMC: 11592880. DOI: 10.3390/curroncol31110527.


Clinical significance of sarcopenia in children with neuroblastic tumors.

Kudo W, Terui K, Furugane R, Takenouchi A, Komatsu S, Kawaguchi Y Pediatr Surg Int. 2024; 40(1):237.

PMID: 39164514 PMC: 11335913. DOI: 10.1007/s00383-024-05815-9.


Preoperative dexamethasone administration in reducing the incidence of nausea and vomiting after thyroidectomy: a systematic review and meta-analysis of drug dosage.

Ye H, Gou J, Li S, Ji Q Gland Surg. 2024; 13(2):189-198.

PMID: 38455354 PMC: 10915429. DOI: 10.21037/gs-23-260.


References
1.
Hung G, Horng J, Lee Y, Yen H, Chen C, Lee C . Cancer incidence patterns among children and adolescents in Taiwan from 1995 to 2009: a population-based study. Cancer. 2014; 120(22):3545-53. PMC: 4232908. DOI: 10.1002/cncr.28903. View

2.
Kowalczyk J, Samardakiewicz M, Fitzgerald E, Essiaf S, Ladenstein R, Vassal G . Towards reducing inequalities: European Standards of Care for Children with Cancer. Eur J Cancer. 2013; 50(3):481-5. DOI: 10.1016/j.ejca.2013.11.004. View

3.
Gatta G, Botta L, Comber H, Dimitrova N, Leinonen M, Pritchard-Jones K . The European study on centralisation of childhood cancer treatment. Eur J Cancer. 2019; 115:120-127. DOI: 10.1016/j.ejca.2019.04.024. View

4.
Sonehara K, Kimura Y, Nakano Y, Ozawa T, Takahashi M, Suzuki K . A common deletion at BAK1 reduces enhancer activity and confers risk of intracranial germ cell tumors. Nat Commun. 2022; 13(1):4478. PMC: 9346128. DOI: 10.1038/s41467-022-32005-9. View

5.
van der Meer D, Karim-Kos H, van der Mark M, Aben K, Bijlsma R, Rijneveld A . Incidence, Survival, and Mortality Trends of Cancers Diagnosed in Adolescents and Young Adults (15-39 Years): A Population-Based Study in The Netherlands 1990-2016. Cancers (Basel). 2020; 12(11). PMC: 7698904. DOI: 10.3390/cancers12113421. View